Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 6 years of EBITDA Margin data on record, last reported at 111.54% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 26114.0% year-over-year to 111.54%; the TTM value through Sep 2025 reached 126.2%, up 265112.0%, while the annual FY2024 figure was 181.4%, N/A changed from the prior year.
  • EBITDA Margin reached 111.54% in Q3 2025 per CYCN's latest filing, up from 1797.85% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 627.5% in Q3 2022 and bottomed at 21611.29% in Q1 2021.
  • Average EBITDA Margin over 4 years is 3144.6%, with a median of 1798.31% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: crashed -1961662bps in 2021, then surged 1978597bps in 2022.
  • A 4-year view of EBITDA Margin shows it stood at 2690.24% in 2021, then soared by 123bps to 627.5% in 2022, then crashed by -96bps to 27.8% in 2024, then tumbled by -501bps to 111.54% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 111.54% in Q3 2025, 1797.85% in Q2 2025, and 1798.77% in Q1 2025.